BioCentury
ARTICLE | Company News

KaloBios cancer news

November 16, 2015 8:00 AM UTC

KaloBios will reduce headcount by about 17 (61%) to about 11 to focus resources on development of lenzilumab ( KB003) in chronic monomyelocytic leukemia (CMML) while it evaluates strategic alternatives, including a potential sale of the company or its assets, wind-down of operations and bankruptcy proceedings. This quarter, KaloBios plans to begin a Phase I trial of the chimeric mAb against GM-CSF developed using Humaneered technology to treat CMML. ...